Combination of anti-HER2 humanized monoclonal antibody and chemotherapy is the first line therapy recommended to patients with metastatic HER2-positive breast cancer, and the antibody-drug conjugate (ADC) trastuzumab emtansine is the standard second-line therapy [9, 10]. Here, ERBB2 is linked to breast carcinoma.